3-28 | by Joanne Liu (the international president of Médecins Sans Frontières.) and Paual Farmer (The co-founder of Partners in Health, Professor of Global Health and Social Medicine at Harvard Medical School, and Chief of the Division of Global Health Equity at Brigham and Women’s Hospital.) Though TB can strike anyone, it disproportionately afflicts marginalized and vulnerable populations in places like refugee camps, slums, and prisons.
3-23 | Despite being curable, the world is losing the battle against tuberculosis (TB). The road ahead is rife with challenges, from diagnosis to treatment, for patients and treatment providers alike. In this Q&A, Dr. Francis Varaine, leader of the MSF working group on Tuberculosis, explains MSF’s priorities over the next ten years. Where are we in the fight against TB? We’re not exactly winning.
3-22 | More than 688,000 Rohingya refugees have arrived in Cox's Bazar, a district in southeast Bangladesh, since late August 2017, after fleeing violence in Rakhine State, Myanmar. They joined several other thousands who had made the same journey in previous crises. The refugees – from a minority Muslim group denied citizenship and other rights in Myanmar – have settled in existing camps, as well as in new makeshift settlements set up by the Bangladeshi authorities in an effort to cope with the humanitarian crisis. Here we recount the journeys of three Rohingya.
12-19 | Cases of cholera may have declined in Yemen, but the ongoing war and blockade are now creating a new threat to public health, as a suspected diphtheria outbreak takes hold. By 4 December, 318 suspected cases of diphtheria and 28 deaths had been reported in 15 of Yemen’s 20 governorates. Half the suspected cases are children between the ages of 5 and 14, and nearly 95% of deaths are children under 15.
MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices
12-18 | Gilead recently launched one of these drugs for $100/pill in China Médecins Sans Frontières (MSF) has filed a legal patent challenge in China against US pharmaceutical corporation Gilead’s patent application for the combination of two crucial oral hepatitis C medicines, sofosbuvir and velpatasvir. This combination is the first direct-acting antiviral (DAA) treatment to be registered for use against all genotypes* of the disease.